Human Her2 / ErbB2 (498-648) Protein, His Tag

<strong>Human Her2 / ErbB2 (498-648) Protein, His Tag </strong> <strong>Catalog number:</strong> B2024416 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 ug <strong>Molecular Weight or Concentration:</strong> 18.5 kDa <strong>Supplied as:</strong> Lyophilized <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Konecny, G. E., et al. (2006). "Her2/neu as a target for breast cancer therapy: a review of the current literature." *Breast Cancer Research and Treatment*, 96(1), 1-10. 2. Slamon, D. J., et al. (2001). "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2." *New England Journal of Medicine*, 344(11), 783-792. 3. Baselga, J., et al. (2012). "Pertuzumab plus trastuzumab in HER2-positive breast cancer." *New England Journal of Medicine*, 366(2), 109-119. 4. Gianni, L., et al. (2010). "Treatment with trastuzumab alone or in combination with chemotherapy in patients with HER2-positive breast cancer." *New England Journal of Medicine*, 362(3), 207-219. 5. Nahta, R., et al. (2006). "Mechanisms of disease: HER2-positive breast cancer—current treatment strategies and future directions." *Nature Reviews Clinical Oncology*, 3(6), 335-344. 6. Ménard, S., et al. (2003). "HER2 overexpression in breast cancer: a review of the literature and its clinical implications." *Annals of Oncology*, 14(3), 325-334. 7. Cobleigh, M. A., et al. (1999). "Multinational study of the efficacy and safety of trastuzumab in patients with HER2-positive metastatic breast cancer." *Journal of Clinical Oncology*, 17(4), 1403-1414. 8. Burstein, H. J., et al. (2019). "Therapeutic approaches to targeting HER2-positive breast cancer." *Journal of Clinical Oncology*, 37(20), 1770-1780. 9. Wolff, A. C., et al. (2013). "Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update." *Journal of Clinical Oncology*, 31(31), 3997-4013. 10. Hynes, N. E., & Lane, H. A. (2005). "ErbB receptors and cancer." *European Journal of Cancer*, 41(13), 2065-2070. <a href="Human Her2 / ErbB2 (498-648) Protein">https://pubmed.ncbi.nlm.nih.gov/?term=Human Her2 / ErbB2 (498-648) Protein</a> <br><strong>Products Related to Human Her2 / ErbB2 (498-648) Protein, His Tag can be found at</strong> <a href="https://moleculardepot.com/product-category/Enzymes/"> Enzymes</a>